A substantive modification. v2 significantly alters the guidance requirements for the Secretary of Health and Human Services from mandatory with specific timelines to discretionary authority. It also includes several technical and clarifying amendments to the biosimilar interchangeability provisions and conforming amendments.
Biosimilar Red Tape Elimination Act
- Sponsor
- Sen. Lee, Mike [R-UT]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jul 27, 2026
Bottom line
The bill aims to accelerate patient access to lower-cost interchangeable biosimilar products by eliminating a distinct regulatory hurdle for interchangeability.
What it actually does
This bill amends the Public Health Service Act to streamline the regulatory pathway for biological products to be deemed interchangeable with their reference products. It eliminates the separate regulatory standard for interchangeability, instead deeming biosimilar products interchangeable upon licensure. The bill includes a transition period and preserves existing first interchangeable exclusivity periods for certain products.
Proponents argue
Proponents argue that the current separate regulatory pathway for interchangeability creates unnecessary delays and costs, hindering market competition and patient access to more affordable biological medicines. They contend that biosimilarity inherently implies interchangeability, and removing this 'red tape' will foster a more robust biosimilar market, leading to significant healthcare cost savings and improved patient outcomes.
Opponents contend
Opponents, particularly some innovator biologic manufacturers, might argue that removing the distinct interchangeability standard could potentially compromise patient safety or physician confidence, as the original standard required additional clinical studies to demonstrate that switching between products would not increase risk. They might also raise concerns about the impact on innovation for novel biologics if the market for biosimilars becomes too aggressive too quickly.
The bill is concise and its core changes are identifiable, making it accessible for a reader to understand its primary intent within a reasonable timeframe.
Section 2(a)(1)
Removal of 'or Interchangeable' from Biosimilar Application Heading
This amendment removes the phrase 'or Interchangeable' from the heading of Section 351(k) of the Public Health Service Act, which governs applications for biosimilar biological products. This change signals the bill's intent to integrate interchangeability directly into the biosimilar approval process rather than treating it as a separate designation.
Supporters argue
Supporters argue this is a necessary technical amendment to align the statutory language with the new policy of deemed interchangeability.
Critics contend
No specific opposition is typically raised against this provision because it is a technical amendment.
Tradeoffs
None apparent for this specific change.
Section 2(a)(2)
Streamlining Biosimilar Application Information Requirements
This section makes several technical amendments to paragraph (2) of Section 351(k), which outlines the information required in an application for a biosimilar product. It strikes subparagraph (B), redesignates existing clauses, and adjusts margins and internal references. The overall effect is to simplify the structure of the application requirements, likely by removing specific requirements related to the separate interchangeability pathway.
Section 2(a)(3)
Clarification of Secretary's Biosimilar Determination Standard
This amendment simplifies the language regarding the Secretary's determination for biosimilar licensure. It states that licensure is granted if the Secretary determines the information is 'sufficient to show that the biological product is biosimilar to the reference product.' This removes any implicit or explicit reference to separate interchangeability standards in the initial licensure determination.
Section 2(a)(4)
Deemed Interchangeability for Biosimilar Products
This crucial amendment establishes that a biological product licensed as biosimilar under Section 351(k) shall be 'deemed to be interchangeable' with its reference product upon licensure. It includes a transition period: products licensed before a 'transition date' (60 days after enactment) are deemed interchangeable on that date. An exception preserves existing 'first interchangeable exclusivity' periods for certain biological products licensed before the bill's enactment, meaning deemed interchangeability would be delayed until that exclusivity ends.
Section 2(a)(5)
Preservation of Existing First Interchangeable Exclusivity
This provision explicitly states that any unexpired period of 'first interchangeable exclusivity' for a biological product licensed before the bill's enactment will remain in effect. This ensures that manufacturers who previously earned this exclusivity under the old framework are not immediately disadvantaged by the new 'deemed interchangeable' standard.
Section 2(b)
Conforming Amendments Across Public Health Service Act and FD&C Act
This subsection makes several conforming amendments to other sections of the Public Health Service Act (PHSA) and the Federal Food, Drug, and Cosmetic Act (FD&C Act). These changes remove references to the previous distinct 'interchangeable biosimilar biological products' or the standards for interchangeability, ensuring consistency with the new 'deemed interchangeable' framework. It also updates language regarding pediatric assessments for biosimilars.
Section 2(c)
FDA Guidance on Biosimilarity Data Requirements
This subsection authorizes the Secretary of Health and Human Services to issue or revise guidance regarding the data and information required to support a determination of biosimilarity, including for combination products. It explicitly states that the issuance or non-issuance of such guidance will not prevent the review or action on biosimilar applications. The reported text makes guidance updates discretionary, unlike the original bill's stronger mandate.
The original bill mandated the Secretary to update existing guidance and issue new guidance within 18 months, with a further revision period. The reported bill changes this to simply 'The Secretary of Health and Human Services may issue or revise guidance, as appropriate,' removing all timelines and making it discretionary.
Section 2(c) (comparison between deleted and reported text)
Why it matters:This is a substantive change made during the committee process, likely a compromise to give the FDA more flexibility or to address concerns about the burden of strict timelines. It's not intentionally 'buried' in the sense of being hidden, but it's a significant alteration from the original intent that requires careful comparison of the two versions.
Case for: Proponents of the discretionary language argue it provides the FDA with necessary flexibility to prioritize guidance updates based on resources and evolving scientific understanding, rather than being bound by rigid statutory deadlines.
Case against: Critics might argue that making guidance discretionary could lead to delays in providing clarity to the industry, thus slowing the adoption and market entry of biosimilars, undermining the bill's primary goal.
Estimated impact: Could impact the speed at which the biosimilar market fully adapts to the new regulatory framework, potentially delaying the realization of cost savings.